CClinicalTrials.gg
Sign In
Not yet recruitingNCT07776587Updated Aug 20, 2026

Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients

An interventional study of Yoga Therapy (YT) in Cancer, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn whether a yoga therapy program can improve quality of life and reduce symptoms in people undergoing stem cell transplantation compared with an enhanced standard care physical activity program.

Read the detailed description

Primary Objective:

  • Examine the efficacy of YT relative to SC on HSCT-specific QOL. Outcomes will be collected at baseline pre-transplant (pre-YT) and then day 0, 14, 30, 60, and 100 as well as 1-year post-transplant.

Secondary Objectives and Endpoints:

  • Examine group differences in other patient-reported outcomes including general QOL and fatigue.
  • Explore group differences in psychosocial and functional outcomes and as possible mediators including stress, mental health (depression and anxiety), sleep disturbances, growth, self-efficacy, mindfulness, and objective functional measures as well as moderators of YT including demographic factors (sex, age, etc.), baseline psychosocial factors, and medical variables (e.g., autologous versus allogeneic transplant).
  • Explore YT's implementation through qualitative interviews.
02

Conditions studied

  • Cancer

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male and female cancer patients
  2. Age 18 or older
  3. Understand and read English
  4. Scheduled to undergo their first autologous or allogeneic HSCT (even number of each) at MDA with a minimum of 2-week inpatient hospital stay
  5. Be willing to follow protocol requirements
  6. Sign a written informed consent

Exclusion criteria

Exclusion Criteria:

  1. Have extreme mobility issues that preclude participating in the Yoga program
  2. Have major thought disorders such as schizophrenia or uncontrolled bipolar disorder
  3. Have hematopoietic cell transplantation HCT comorbidity score of 3 or higher (excluding cancer)
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    SC: Enhanced Stand of Care Group

    In the experimental \& control interventions: participants will receive up to 3 sessions per week, for a total of up to 10 weeks or 20 sessions, whichever comes first

    Other: Yoga Therapy (YT)

  • Experimental
    YT: Yoga Group

    In the experimental \& control interventions: participants will receive up to 3 sessions per week, for a total of up to 10 weeks or 20 sessions, whichever comes first

    Other: Yoga Therapy (YT)

Interventions

  • OtherYoga Therapy (YT)

    Yoga Therapy (YT) is an evidence-based mind-body practice recommended for cancer to relieve nausea, fatigue, pain, sleep disruption, psychosocial distress, musculoskeletal symptoms, and cognitive dysfunction, all common symptoms experienced during HSCT.

05

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year

06

Study locations

1 site
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
    • Lorenzo Cohen, PHD · Contact · lcohen@mdanderson.org · 713-745-4260
    • Lorenzo Cohen, PHD · Principal investigator
07

References and documents

08

Registry details

Key details

Study ID
NCT07776587
Lead sponsor
M.D. Anderson Cancer Center
Collaborators
National Institutes of Health (NIH)
Responsible party
Sponsor
First posted
Aug 20, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Apr 13, 2030 (estimated)
Completion
Apr 13, 2032 (estimated)
Last update
Aug 20, 2026

Study contacts

Lorenzo Cohen, PHD
Contact
lcohen@mdanderson.org
(713) 745-4260
Lorenzo Cohen, PHD
principal investigator · UT MD Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

M.D. Anderson Cancer Center

Start the discussion